Shandong Lukang Pharmaceutical Co.,Ltd. operates as a pharmaceutical company in China. The company offers systemic anti-infectives, hypoglycemic agents, cardiovascular and cerebrovascular drugs, respiratory medicines, neurodegenerative disease treatments, digestive and metabolic disease drugs, antitumor drugs, and traditional Chinese and Tibetan medicines. The company also provides synthetic biology products, including trans-aconitic acid, perillyl alcohol, bisabolol, and patchouli alcohol, and engages in the production and sale of feed additives and import-export trade; and ceftriaxone sodium, acetylspiramycin, amoxicillin, tadalafil tablets, acarbose, rosuvastatin, isosorbide mononitrate sustained-release tablets, and various veterinary antibiotics and preparations. In addition, the company engages in hazardous waste treatment, environmental protection engineering, equipment installation and maintenance, and production and sale of biological pesticides. The company was formerly known as Jining Antibiotic Factory and changed its name to Shandong Lukang Pharmaceutical Co.,Ltd. in October 1993. Shandong Lukang Pharmaceutical Co.,Ltd. was founded in 1966 and is headquartered in Jining, China.
Research context
Shandong Lukang Pharmaceutical Co.,Ltd appears in PyInvesting’s Shanghai Stock catalogue. The price history above describes this recorded instrument; it does not by itself identify a company’s business or establish a continuous investment return.
- Currency
- CNY
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
These are the latest stored catalogue classifications, not a historical classification snapshot. An issuer description, classification effective date or currency may be unavailable. Check the issuer’s own disclosures and the observation dates before using these fields for research.
Review backtest assumptions and evidence before treating a chart or stored history as a research result.
5 years, 6 months ago
Shandong Lukang Pharmaceutical Co.,Ltd is currently in a long term downtrend where the price is trading 10.6% below its 200 day moving average.
From a valuation standpoint, the stock is 83.4% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 1.6.
Shandong Lukang Pharmaceutical Co.,Ltd's total revenue rose by 21.4% to $1B since the same quarter in the previous year.
Its net income has dropped by 91.0% to $2M since the same quarter in the previous year.
Finally, its free cash flow grew by 68.6% to $-55M since the same quarter in the previous year.
Based on the above factors, Shandong Lukang Pharmaceutical Co.,Ltd gets an overall score of 3/5.